

Long-Term Cognitive Decline After Newly Diagnosed Heart Failure

Longitudinal Analysis in the CHS (Cardiovascular Health Study)

BACKGROUND: Heart failure (HF) is associated with cognitive impairment. However, we know little about the time course of cognitive change after HF diagnosis, the importance of comorbid atrial fibrillation, or the role of ejection fraction. We sought to determine the associations of incident HF with rates of cognitive decline and whether these differed by atrial fibrillation status or reduced versus preserved ejection fraction.

METHODS AND RESULTS: Participants were 4864 men and women aged ≥ 65 years without a history of HF and free of clinical stroke in the CHS (Cardiovascular Health Study)—a community-based prospective cohort study in the United States, with cognition assessed annually from 1989/1990 through 1998/1999. We identified 496 participants with incident HF by review of hospital discharge summaries and Medicare claims data, with adjudication according to standard criteria. Global cognitive ability was measured by the Modified Mini-Mental State Examination. In adjusted models, 5-year decline in model-predicted mean Modified Mini-Mental State Examination score was 10.2 points (95% confidence interval, 8.6–11.8) after incident HF diagnosed at 80 years of age, compared with a mean 5-year decline of 5.8 points (95% confidence interval, 5.3–6.2) from 80 to 85 years of age without HF. The association was stronger at older ages than at younger ages, did not vary significantly in the presence versus absence of atrial fibrillation ($P=0.084$), and did not vary significantly by reduced versus preserved ejection fraction ($P=0.734$).

CONCLUSIONS: Decline in global cognitive ability tends to be faster after HF diagnosis than without HF. Clinical and public health implications of this finding warrant further attention.

Christa A. Hammond, MS
Natalie J. Blades, PhD
Sarwat I. Chaudhry, MD
John A. Dodson, MD, MPH
W.T. Longstreth, Jr, MD
Susan R. Heckbert, MD,
PhD
Bruce M. Psaty, MD, PhD
Alice M. Arnold, PhD
Sascha Dublin, MD, PhD
Colleen M. Sitlani, PhD
Julius M. Gardin, MD,
MBA
Stephen M. Thielke, MD,
MSPH
Michael G. Nanna, MD
Rebecca F. Gottesman,
MD, PhD
Anne B. Newman, MD,
MPH
Evan L. Thacker, PhD

Correspondence to: Evan L. Thacker, PhD, Department of Public Health, Brigham Young University, 2051 Life Sciences Bldg, Provo, UT 84602. E-mail elt@byu.edu

Key Words: aged ■ atrial fibrillation ■ cognition ■ cohort studies ■ heart failure

© 2018 American Heart Association, Inc.

WHAT IS NEW?

- Global cognitive ability declined significantly faster after newly diagnosed (incident) heart failure (HF) relative to no history of HF, in the absence of clinical stroke.
- The faster rate of decline after incident HF was evident across all ages between 70 and 90 years and was significantly more pronounced at older ages.
- The association of incident HF with more rapid cognitive decline did not differ significantly by whether participants had concomitant atrial fibrillation.
- The rate of cognitive decline after incident HF did not differ significantly by whether ejection fraction was reduced or preserved.

WHAT ARE THE CLINICAL IMPLICATIONS?

- Clinicians may use our estimates of cognitive trajectories to anticipate average rates of cognitive decline that may occur in their populations of patients who have newly diagnosed HF.

Hear failure (HF) is a common chronic condition in older adults and is associated with cognitive impairment and dementia,^{1–3} which lead to difficulties in self-care and higher risks for hospitalization and mortality.^{4–7} Our understanding of the time course of cognitive change in HF is limited because most prior longitudinal studies of cognitive decline in HF were based on small groups of participants with HF, had <1 year of follow-up, lacked non-HF comparison groups, or had inadequate adjustment for vascular risk factors.^{8,9} A few longitudinal studies with follow-up beyond 1 year and non-HF comparison groups provide some evidence that HF is associated with faster cognitive decline.^{10–13} However, those studies, too, were limited by including relatively small groups of participants, combining people who had a history of HF at baseline with those who had incident HF diagnosed during follow-up without accounting for time elapsed since HF diagnosis, or grouping together cognitive test scores obtained before and after incident HF diagnosis to estimate cognitive trajectories. Therefore, there is a need for results from larger long-term studies of participants with incident HF, with statistical modeling that differentiates between cognitive test scores obtained before versus after HF diagnosis, to estimate how quickly cognition declines after incident HF diagnosis.

HF often manifests with concomitant atrial fibrillation (AF). In a previous analysis, we showed that incident AF was associated with faster cognitive decline in older adults.¹⁴ Would HF and AF interact synergistically in relation to long-term cognitive decline? Data to

address this question are sparse. In several cross-sectional studies of people with HF, those with concomitant AF had higher odds of cognitive impairment than those without AF.¹⁵ However, prior longitudinal studies did not assess whether long-term cognitive trajectories in HF differed according to AF status.

Another gap in our understanding of HF and long-term cognitive decline relates to left ventricular ejection fraction (EF). Would HF with reduced EF have a stronger relationship with cognitive decline than HF with preserved EF? Data to address this issue are limited. Cross-sectional data suggest that cognitive performance in people with HF varies according to whether EF is reduced or preserved.^{16,17} However, prior longitudinal studies did not compare long-term cognitive trajectories in people with HF who had reduced versus preserved EF.

To address these knowledge gaps, we sought to determine associations of incident HF and duration of HF with long-term cognitive trajectories and whether these associations differed by presence versus absence of AF or by reduced versus preserved EF. We used cognitive measures obtained longitudinally in a large community-based cohort of older adults in which newly diagnosed HF was identified during follow-up, and statistical models that differentiated between cognitive test scores obtained before and after incident HF diagnosis. Our goal was to produce estimates of average cognitive trajectories after incident HF diagnosis, which would allow people with newly diagnosed HF, their families, and clinicians to anticipate the average rate at which cognitive decline may occur.

METHODS

Design, Setting, and Participants

The CHS (Cardiovascular Health Study)—a community-based longitudinal study—was conducted to identify risk factors for and consequences of cardiovascular diseases in older adults.¹⁸ CHS included 5888 men and women aged ≥65 years enrolled in 1989/1990 and 1992/1993 in Sacramento County, CA; Washington County, MD; Forsyth County, NC; and Allegheny County, PA. For this analysis, participants were followed through 1998/1999. Prevalent cardiovascular disease and risk factors were ascertained at enrollment.¹⁹ Updated risk factor data and functional measures, including cognitive performance, were collected at annual clinic visits through 1998/1999. Incident cardiovascular events were ascertained throughout follow-up and adjudicated according to standard criteria.^{20,21} Participants were included in this analysis if they did not have prevalent HF at enrollment, had at least 1 cognitive assessment obtained at enrollment or during follow-up, and had complete covariate data (Figure 1 in the [Data Supplement](#)). Participants who had a history of clinical stroke at enrollment were excluded, and participants were censored at occurrence of incident clinical stroke because stroke is known to be associated with more rapid

cognitive decline, and therefore, we wanted to focus on cognitive trajectories in people free of clinical stroke. Institutional Review Boards at the coordinating center at the University of Washington and each field center approved the study, and participants gave written informed consent. The Institutional Review Board at Brigham Young University approved the use of these data for this analysis. Requests to access the data set from qualified researchers trained in human subjects confidentiality protocols may be sent to the Collaborative Health Studies Coordinating Center (<https://www.uwchsc.org>) at the University of Washington, Seattle, WA.

Assessment of HF and EF

History of HF before enrollment was identified by participant report and verified by medical record review.¹⁹ During follow-up, hospitalizations were identified by participant report and discharge diagnoses from Medicare data.²⁰ Following these reports, incident HF was identified and confirmed by review of outpatient or inpatient medical records and diagnostic tests.^{20–23} The CHS Events Committee adjudicated incident HF on the basis of appropriate symptoms and signs of HF in the medical record, pulmonary edema on chest radiograph or other supporting clinical findings, or medication prescribed for HF.^{20–23} After a confirmed incident HF diagnosis, a participant was considered to have HF throughout the remainder of follow-up for this analysis.

Approximately 50% of participants who developed incident HF had left ventricular EF data at the time of HF diagnosis available from medical record review (Figure I in the [Data Supplement](#)), derived from echocardiography, cardiac catheterization, multigated acquisition scanning, or other modalities. For this analysis, we classified EF <45% as reduced EF, and EF ≥45% as preserved EF. We did not include EF data in this analysis for participants who did not develop incident HF.

Assessment of AF

AF was identified by electrocardiograms obtained at annual clinic visits and hospital discharge diagnosis codes.^{19,24,25}

Assessment of Cognitive Function

Global cognitive function was assessed longitudinally using the 100-point Modified Mini-Mental State Examination (3MSE).²⁶ The 3MSE was administered annually, up to 9x per participant from 1990/1991 through 1998/1999. The 3MSE includes questions assessing memory, orientation, fluency, problem solving, and ability to follow instructions, yielding a global cognitive score between zero (worst) and 100 (best). During 1995/1996 to 1998/1999, for participants not able to complete an in-person examination, telephone-based measures of global cognitive performance were obtained, including the Telephone Interview for Cognitive Status and the Informant Questionnaire on Cognitive Decline in the Elderly.^{27,28} These were used to estimate the missing 3MSE scores using equations previously developed for CHS data (Figure I in the [Data Supplement](#)).²⁹

Processing speed was assessed longitudinally using the Digit Symbol Substitution Test (DSST).³⁰ The DSST was administered annually, up to 10x per participant from 1989/1990 through 1989/1999. The DSST consists of a visual motor task

in which, for 90 seconds, a person matches symbols with correct digits according to a key, yielding a measure of information processing speed on a scale of zero (worst) to 90 (best).

Assessment of Other Variables

Age, birth year, sex, race, years of education, and use of cigarettes and alcohol were determined by participant report. Medication use was determined by annual medication inventory.³¹ Creatinine, hemoglobin, and glucose were measured in blood samples.³² Blood pressure was recorded as the average of 2 measurements. Body mass index was calculated from measured height and weight. Chronic obstructive pulmonary disease was identified by participant report. Chronic kidney disease was defined as estimated glomerular filtration rate <60 mL/min per 1.73 m² based on serum creatinine and the Chronic Kidney Disease Epidemiology Collaboration equation.³³ Anemia was defined as hemoglobin <13 g/dL for men and <12 g/dL for women.³⁴ Stroke and coronary heart disease were identified by participant report or proxy report, confirmed by medical record review and adjudicated according to standard criteria.^{19–21,35} Diabetes mellitus was defined as the use of insulin or oral hypoglycemic medications or fasting serum glucose ≥126 mg/dL or nonfasting serum glucose ≥200 mg/dL. Hypertension was defined as self-reported physician-diagnosed hypertension plus use of antihypertensive medication or systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg. Stroke, coronary heart disease, AF, diabetes mellitus, and hypertension status were initially defined at enrollment and then updated during follow-up. A participant was considered to have diabetes mellitus through the end of follow-up after the first observed elevated glucose or reported use of antidiabetic medication. All other covariates were defined at enrollment and considered non-time-varying.

Statistical Analysis

We developed statistical models separately for each cognitive function test (3MSE and DSST). We used linear mixed models with age as the time scale to model the relationship of incident HF with longitudinal cognitive trajectory.³⁶ Incident HF was a time-varying variable, coded as absent (zero) at the beginning of follow-up for all participants, and then recoded to present (1) part of the way through follow-up at the age of HF diagnosis for participants who experienced incident HF. We considered intercept, age, and age-squared to be random at the participant level and included them as random effects with a spatial exponential covariance structure. We included incident HF and time elapsed since incident HF diagnosis as time-varying fixed effects; and the following 4 multiplicative interaction terms of HF variables with age variables as fixed effects: incident HF×age, incident HF×age-squared, time elapsed since incident HF diagnosis×age, and time elapsed since incident HF diagnosis×age-squared. Thus, average cognitive performance with no history of HF at any given age was based on cognitive test scores obtained from participants with no history of HF at that age, including those participants who went on to experience incident HF at older ages (Figure I in the [Data Supplement](#)). We also included other variables

listed above as fixed effects to adjust for potential confounding. To determine whether the cognitive trajectory across age differed significantly by incident HF, we used an *F* test to simultaneously test the 4 interaction terms, thereby comparing our primary model as specified above with a simpler model that did not include interactions of HF variables with age variables. We graphed model-predicted cognitive trajectories according to age and HF status and calculated model-predicted 5-year declines in cognitive performance without HF and after incident HF diagnosis.

To explore whether the association of incident HF with cognitive decline differed according to presence versus absence of AF, we augmented the models described above with multiplicative interaction terms for AF with incident HF and age variables as fixed effects, including four 2-way interaction terms: AF×incident HF, AF×time elapsed since incident HF diagnosis, AF×age, and AF×age-squared; and four 3-way interaction terms: AF×incident HF×age, AF×incident HF×age-squared, AF×time elapsed since incident HF diagnosis×age, and AF×time elapsed since incident HF diagnosis×age-squared. We used 2 different *F* tests to assess this model. First, to determine whether cognitive trajectories estimated from our primary model differed overall by AF status, we simultaneously tested all 8 interaction terms involving AF, thereby comparing this model with our primary model. Second, to determine whether the differences in cognitive trajectory across age by incident HF further differed significantly by AF status, we simultaneously tested the four 3-way interaction terms involving AF, HF, and age variables, thereby comparing this model with an intermediate model that included only 2-way interactions of AF with HF and age variables but no 3-way interactions. We graphed model-predicted cognitive trajectories and calculated model-predicted 5-year declines in cognitive performance, similar to the primary analysis but stratified by AF status.

To explore the association of EF with rate of cognitive decline after HF diagnosis, we classified each participant with HF as having reduced EF, preserved EF, or unknown EF. For these models, we included only post-HF cognitive test scores; used time since incident HF diagnosis as the time scale instead of age; included intercept and time as random effects; included EF category and EF category×time as fixed effects; and adjusted for age at incident HF diagnosis, sex, race, and education as fixed effects. We considered a time-squared term but omitted it because it did not significantly improve the estimate of average cognitive test score trajectory over time; a linear term for time since incident HF diagnosis was sufficient. Using this simpler model, we estimated model-predicted 5-year declines in cognitive performance after incident HF diagnosis for each EF category.

In a sensitivity analysis, we omitted participants who had only 1 cognitive assessment and analyzed only participants who had multiple cognitive assessments over time. In another sensitivity analysis, we omitted 3MSE scores estimated from telephone-based cognitive assessments and analyzed only directly measured 3MSE scores.

Statistical analyses were conducted in SAS, version 9.4 (SAS Institute, Cary, NC), and R, version 3.2.4 (R Development Core Team, www.r-project.org). Dr Thacker had full access to all the data in the study and took responsibility for its integrity and the data analysis.

RESULTS

Incident HF and Participant Characteristics

Incident HF was identified in 496 (10.2%) of 4864 participants during a mean of 6.4 years of follow-up (maximum of 8 years) in 3MSE analyses and in 389 (7.8%) of 4969 participants during a mean of 6.5 years of follow-up (maximum of 9 years) in DSST analyses. A greater number of incident HF cases were identified in 3MSE analyses than for DSST analyses because follow-up for 3MSE analyses was extended into older ages for some participants by estimating missing 3MSE scores using telephone-based cognitive measures (see above and Figure I in the [Data Supplement](#)). Participants who developed incident HF were on average older, more often men, of white race, and at higher cardiovascular risk than those who did not develop incident HF (Table 1; Table I in the [Data Supplement](#)).

Modified Mini-Mental State Examination

We analyzed 34 854 3MSE scores obtained from 4864 participants, representing >90% of potential 3MSE scores that could have been obtained had there been no censoring and no missed exams. A summary of 3MSE scores not obtained or not analyzed because of censoring or missed exams is given in Figure I in the [Data Supplement](#). Model-predicted trajectories of mean 3MSE score are illustrated in Figure 1A. With no history of HF (solid curve), mean 3MSE declined steeply after 75 years of age. Model-predicted trajectories of mean 3MSE score after incident HF diagnosed at ages 70, 75, 80, and 85 are shown in 4 dashed curves. Mean 3MSE score declined faster after incident HF diagnosis relative to no history of HF. For example, decline in mean 3MSE score from 80 to 85 years of age was 10.2 points (95% confidence interval, 8.6–11.8) after incident HF diagnosed at 80 years of age, compared with mean decline of 5.8 points (95% confidence interval, 5.3–6.2) from 80 to 85 years of age without HF (Table 2). We observed age-related differences in the association of incident HF with mean 3MSE score: older age at HF diagnosis was associated with larger differences in trajectories of mean 3MSE score after HF diagnosis relative to no history of HF. Model coefficients and standard errors are in Table II in the [Data Supplement](#).

Digit Symbol Substitution Test

We analyzed 34 769 DSST scores obtained from 4969 participants, representing >84% of potential DSST scores that could have been obtained had there been no censoring and no missed exams. A summary of DSST scores not obtained or not analyzed because of censoring or missed exams is given in Figure I in the [Data Supplement](#). Model-predicted trajectories of mean

Table 1. Characteristics at Study Enrollment, and Incident Conditions by Incident HF for Participants Included in Analysis of 3MSE*

Characteristic	Participants Diagnosed With Incident HF During Follow-Up (n=496)	Participants Not Diagnosed With Incident HF During Follow-Up (n=4368)
Age, y; mean (SD)	75.7 (6.0)	73.7 (5.3)
Birth, y; mean (SD)	1915 (6.0)	1917 (5.4)
Men, %	50.4	40.6
Black race, %	11.7	14.5
Years of education through 12th grade, mean (SD)	10.7 (2.3)	11.1 (1.9)
Any education beyond 12th grade, %	40.1	44.3
Former smoking, %	43.8	41.7
Current smoking, %	12.5	11.6
Any current alcohol use, %	43.1	52.7
Drinks per week, mean (SD)	4.4 (7.0)	5.1 (8.7)
β-Blocker use, %	16.5	12.1
Angiotensin-converting enzyme inhibitor use, %	7.1	5.9
Systolic blood pressure, mmHg; mean (SD)	140.9 (22.5)	135.3 (21.2)
Body mass index, kg/m ² ; mean (SD)	27.5 (5.1)	26.5 (4.5)
Chronic kidney disease, %	44.0	36.7
Chronic obstructive pulmonary disease, %	15.9	12.1
Anemia, %	8.5	7.3
Diabetes mellitus		
At enrollment, %	24.4	13.1
Incident, %	7.5	4.3
Hypertension		
At enrollment, %	65.5	55.6
Incident, %	14.9	16.4
Coronary heart disease		
At enrollment, %	30.8	14.9
Incident, %	30.4	7.0
AF		
At enrollment, %	5.2	1.6
Incident, %	33.3	6.5

3MSE indicates Modified Mini-Mental State Examination; AF, atrial fibrillation; and HF, heart failure.

*The 4864 participants included in this table (496+4368) had at least 1 3MSE score and were included in regression models for 3MSE.

†All percentages in the table are column percentages. Mean drinks per week was calculated among participants who reported any current alcohol use. For diabetes mellitus, hypertension, coronary heart disease, and AF, percentages of participants with the condition present at enrollment and of those with the incident condition occurring during follow-up were mutually exclusive and, therefore, sum to the total percentage of participants with the condition either present at enrollment or occurring during follow-up (mean of 6.4 y). Incident diabetes mellitus, hypertension, coronary heart disease, or AF may have occurred before or after incident HF diagnosis.

DSST score are illustrated in Figure 1B. Rate of decline in mean DSST score with advancing age was not significantly different after incident HF relative to no history of HF. For example, decline in mean DSST score from 80 to 85 years of age was 6.1 points (95% confidence interval, 4.4–7.8) after incident HF diagnosed at age 80 years of age, compared with mean decline of 4.7 points (95% confidence interval, 4.4–5.0) from 80 to 85 years of age without HF (Table 3)—a statistically nonsignificant difference. We did not observe age-related differences in the association of incident HF with mean DSST score; differences in trajectories of mean DSST score after HF diagnosis relative to no history of HF were similar across the age range. Model coefficients and standard errors are in Table II in the [Data Supplement](#).

Interaction of AF With Incident HF

Model-predicted trajectories of mean 3MSE score in the presence or absence of AF are shown in Figure 2A and 2B. Overall, 3MSE trajectories were significantly different in the presence of AF versus absence of AF ($P=0.027$); this overall difference was explained by mean model-predicted 3MSE score declining more quickly with age in the presence of AF than in its absence, regardless of incident HF, especially at older ages (Figure 2A). However, the magnitude of accelerated decline in 3MSE score after incident HF diagnosis was not significantly different in the presence versus absence of AF ($P=0.084$; for magnitudes of these differences, see Table 4). Overall trajectories of DSST score were not significantly different by AF status ($P=0.339$), nor were differences in decline in DSST score by incident HF significantly different by AF status ($P=0.505$; Figure 2C and 2D; Table 4).

HF With Reduced, Preserved, or Unknown EF

After HF diagnosis, rates of cognitive decline by EF category were not significantly different (Table 5). Precision of these estimates was poor because of relatively sparse data within each EF category.

Sensitivity Analyses

Results were similar when we omitted participants who had only 1 cognitive assessment or when we omitted 3MSE scores estimated from telephone-based cognitive assessments.

DISCUSSION

In this longitudinal study of older adults, participants who developed incident HF experienced faster




Figure 1. Model-predicted trajectories of mean Modified Mini-Mental State Examination (3MSE) score and Digit Symbol Substitution Test (DSST) score with no history of heart failure (HF) or after incident HF.

A, Model-predicted trajectories of 3MSE score. **B**, Model-predicted trajectories of DSST score. In each graph, solid curve represents model-predicted mean cognitive test score trajectory with no history of HF. Four dashed curves represent model-predicted mean cognitive test score trajectories after incident HF diagnosed at ages 70, 75, 80, and 85 y. Shading represents 95% confidence bands. Trajectories are adjusted for birth year, sex, race, education, cigarette smoking, alcohol use, β -blocker use, angiotensin-converting enzyme inhibitor use, systolic blood pressure, body mass index, chronic kidney disease, chronic obstructive pulmonary disease, anemia, diabetes mellitus, hypertension, coronary heart disease, and atrial fibrillation. *F* test $P=0.011$ for whether 3MSE trajectory across age differed by incident HF. *F* test $P=0.479$ for whether DSST trajectory across age differed by incident HF.

average decline in global cognitive ability than their peers of the same age who had no history of HF. Differences between the rates of decline in 3MSE score after incident HF diagnosis versus with no history of HF were larger at older ages than at younger ages. We are unable to conclude that there is an association of incident HF with decline in psychomotor processing speed. The association of incident HF with decline in DSST score was smaller in magnitude than the association with decline in 3MSE score, fell short of statistical significance, and did not vary significantly by age.

Four previous studies with follow-up >1 year compared cognitive trajectories in adults with versus with-

out HF (Table III in the [Data Supplement](#)).^{10–13} Their results did not support a consistent profile of cognitive deficits in people with HF but rather suggested that an association of HF with cognitive decline can be detected by some neuropsychological tests when a variety of tests are used. Our study agreed with 1 prior study¹² in finding a statistically significant association of HF with faster decline in global cognitive ability and with 3 prior studies^{10–12} in finding that the association of HF with rate of decline in processing speed (DSST) was small in magnitude and not statistically significant.

Our study has several methodologic strengths. First, we excluded participants who had prevalent HF at study

Table 2. Model-Predicted 5-y Declines in Mean 3MSE Score, by Age and Incident HF

HF*	Predicted 5-y Decline (95% Confidence Interval)†			
	70–75 y of Age	75–80 y of Age	80–85 y of Age	85–90 y of Age
No HF diagnosed before or during the 5-y interval	0.3 (0.0–0.6)	3.0 (2.8–3.3)	5.8 (5.3–6.2)	8.5 (7.7–9.2)
Incident HF diagnosed at beginning of the 5-y interval	2.8 (0.7–4.9)	6.1 (4.6–7.5)	10.2 (8.6–11.8)	15.2 (13.1–17.4)
Difference (incident HF minus no HF)	2.5 (0.4–4.6)	3.0 (1.6–4.4)	4.4 (2.8–6.0)	6.7 (4.6–8.8)

3MSE indicates Modified Mini-Mental State Examination; and HF, heart failure.

**F* test $P=0.011$ for whether 3MSE trajectory across age differed by incident HF.

†Adjusted for birth year, sex, race, education, cigarette smoking, alcohol use, β -blocker use, angiotensin-converting enzyme inhibitor use, systolic blood pressure, body mass index, chronic kidney disease, chronic obstructive pulmonary disease, anemia, diabetes mellitus, hypertension, coronary heart disease, and AF. Participants were censored at the development of clinically recognized stroke.

Table 3. Model-Predicted 5-y Declines in Mean DSST Score, by Age and Incident HF

HF*	Predicted 5-y Decline (95% Confidence Interval)†			
	70–75 y of Age	75–80 y of Age	80–85 y of Age	85–90 y of Age
No HF diagnosed before or during the 5-y interval	1.0 (0.8 to 1.2)	2.8 (2.6 to 3.0)	4.7 (4.4 to 5.0)	6.5 (6.0 to 6.9)
Incident HF diagnosed at beginning of the 5-y interval	3.1 (0.8 to 5.4)	4.1 (2.7 to 5.5)	6.1 (4.4 to 7.8)	9.0 (6.3 to 11.8)
Difference (incident HF minus no HF)	2.1 (–0.2 to 4.4)	1.3 (–0.1 to 2.7)	1.5 (–0.2 to 3.2)	2.5 (–0.2 to 5.3)

DSST indicates Digit Symbol Substitution Test; and HF, heart failure.

*F test $P=0.479$ for whether DSST trajectory across age differed by incident HF.

†Adjusted for birth year, sex, race, education, cigarette smoking, alcohol use, β -blocker use, angiotensin-converting enzyme inhibitor use, systolic blood pressure, body mass index, chronic kidney disease, chronic obstructive pulmonary disease, anemia, diabetes mellitus, hypertension, coronary heart disease, and AF. Participants were censored at the development of clinically recognized stroke.

enrollment, modeled cognitive trajectories after incident HF diagnosis, and used time-varying variables for incident HF and time elapsed since incident HF. Second, we excluded participants who had a history of clinically recognized stroke, and censored participants when they developed clinical stroke, allowing us to rule out the possibility that accelerated cognitive decline after HF diagnosis is explained merely by a higher rate of clinical stroke. Third, we used interaction terms between age and HF variables in our statistical models, enabling us to observe that the association of incident HF with 3MSE trajectory differed by age. Fourth, we conducted a large study with long follow-up, allowing us to graph model-predicted trajectories with excellent precision.

In our previously published work on AF and cognitive decline,¹⁴ our model predicted that people diagnosed with incident AF at 80 years of age would experience on average a 9- to 12-point decline in 3MSE score during the next 5 years, whereas people the same age without AF would experience only a 6- to 7-point decline during 5 years. Similarly, in this new analysis, we observed that people diagnosed with incident HF at 80 years of age would be expected to show on average a 9- to 12-point decline during 5 years, compared with an average 5- to 6-point decline without HF. To build on this understanding that both AF and HF are independently associated with cognitive decline, in the present work, we took a further step, using more complex models to assess whether AF and HF would interact synergistically to hasten cognitive decline. For 3MSE, when we assessed the possibility of an interaction of AF with incident HF, we found that average cognitive performance declined faster, overall, in the presence of AF, as we would expect from our prior work.¹⁴ However, we did not see evidence of synergism between AF and HF; rather, we observed that the magnitude of the association of incident HF with rate of cognitive decline was not significantly different in the presence versus absence of AF. Our results are congruent with previously published cross-sectional data showing that patients with HF who also had AF were more likely to

be cognitively impaired,¹⁵ but this observation may be explained by independent effects of AF and HF, rather than by an interaction of AF with HF.

We observed similar degrees of cognitive decline after HF diagnosis among participants with reduced EF, those with preserved EF, and those with unknown EF. Although we hypothesized that reduced EF would be associated with faster cognitive decline than preserved EF on the basis of previously published research,^{16,17} our results did not support this hypothesis. Unfortunately, we lacked precision to detect significant differences in rates of cognitive decline after incident HF diagnosis by EF category. Therefore, answering this question will require further investigation in other settings.

Our study has limitations. First, we did not have tests of specific cognitive domains other than psychomotor processing speed. Second, we had low statistical power to investigate whether EF category was associated with different cognitive trajectories. Third, our results may have been influenced by nonrandom loss to follow-up (Figure I in the [Data Supplement](#)). Individuals who have cognitive impairment or HF are more likely to miss cognitive assessments than those who are cognitively intact and free of HF, leading to underestimated average rates of cognitive decline.³⁷ Fourth, shared risk factors for HF and cognitive decline, such as genetics, patterns of physical activity or diet, and severity or duration of diabetes mellitus and hypertension, may have confounded the association of HF with cognitive change, even in our adjusted models. Fifth, our data were collected in the 1990s and are, therefore, ≥ 20 years old. However, the high-quality study design, community-based sample, data collection, length of follow-up, and statistical analysis make these data ideal for studying the epidemiology of incident HF and long-term cognitive decline.

It is biologically plausible that HF could cause cognitive decline. Neuroimaging studies suggest that many brain regions involved in cognition sustain injury in HF.³⁸ Commonly cited mechanisms by which HF is thought to reduce cognitive ability are cerebral hypoperfusion and cerebral microemboli.^{4,5,39} How-




Figure 2. Model-predicted trajectories of mean Modified Mini-Mental State Examination (3MSE) score and Digit Symbol Substitution Test (DSST) score with no history of heart failure (HF) or after incident HF, by atrial fibrillation (AF) status.

A, Model-predicted trajectories of 3MSE score in the presence of AF. **B**, Model-predicted trajectories of 3MSE score in the absence of AF. **C**, Model-predicted trajectories of DSST score in the presence of AF. **D**, Model-predicted trajectories of DSST score in the absence of AF. In each graph, solid curve represents model-predicted mean cognitive test score trajectory with no history of HF. Four dashed curves represent model-predicted mean cognitive test score trajectories after incident HF diagnosed at ages 70, 75, 80, and 85 y. Shading represents 95% confidence bands. Trajectories are adjusted for birth year, sex, race, education, cigarette smoking, alcohol use, β -blocker use, angiotensin-converting enzyme inhibitor use, systolic blood pressure, body mass index, chronic kidney disease, chronic obstructive pulmonary disease, anemia, diabetes mellitus, hypertension, and coronary heart disease. *F* test $P=0.027$ for whether 3MSE trajectories differed overall by AF status. *F* test $P=0.084$ for whether the difference in 3MSE trajectory by incident HF further differed by AF status. *F* test $P=0.339$ for whether DSST trajectories differed overall by AF status. *F* test $P=0.505$ for whether the difference in DSST trajectory by incident HF further differed by AF status.

ever, those explanations may not be sufficient. Subclinical left ventricular dysfunction is associated with neuropsychological dysfunction and subclinical vascular brain injury, suggesting relatively subtle mechanisms.^{40–42} Additional mechanisms could include systemic inflammation, oxidative damage, homocysteinemia, elevated B-type natriuretic peptide, thia-

mine deficiency, neurohormonal dysfunction, altered cellular metabolism, and impaired cerebrovascular reactivity.^{1,5,38,43–46} Alternatively, HF may be a marker of underlying nonspecific influences on cognitive ability, such as poor general health, overall burden of illness, hospitalization, multimorbidity, polypharmacy, or fatigue.⁴⁶

Table 4. Model-Predicted 5-y Decline in Mean 3MSE Score and DSST Score, by Age, Incident HF, and AF Status

HF	Predicted 5-y Decline (95% Confidence Interval)*			
	70–75 y of Age	75–80 y of Age	80–85 y of Age	85–90 y of Age
3MSE by age and HF; in the presence of AF†				
No HF diagnosed before or during the 5-y interval	0.0 (–0.9 to 0.8)	3.2 (2.7 to 3.7)	6.4 (5.7 to 7.2)	9.7 (8.4 to 10.9)
Incident HF diagnosed at beginning of the 5-y interval	3.8 (0.5 to 7.1)	7.2 (5.0 to 9.3)	10.8 (7.8 to 13.8)	14.7 (9.2 to 20.1)
Difference (incident HF minus no HF)‡	3.8 (0.4 to 7.3)	4.0 (1.8 to 6.2)	4.4 (1.3 to 7.4)	5.0 (–0.5 to 10.5)
3MSE by age and HF; in the absence of AF†				
No HF diagnosed before or during the 5-y interval	0.3 (0.1 to 0.6)	3.0 (2.7 to 3.3)	5.7 (5.2 to 6.2)	8.4 (7.6 to 9.1)
Incident HF diagnosed at beginning of the 5-y interval	2.4 (–0.3 to 5.1)	5.2 (3.4 to 7.0)	9.4 (7.3 to 11.6)	15.2 (11.9 to 18.4)
Difference (incident HF minus no HF)‡	2.1 (–0.6 to 4.8)	2.2 (0.3 to 4.0)	3.7 (1.6 to 5.9)	6.8 (3.6 to 10.0)
DSST by age and HF; in the presence of AF§				
No HF diagnosed before or during the 5-y interval	1.5 (0.6 to 2.4)	2.9 (2.4 to 3.4)	4.3 (3.7 to 4.9)	5.7 (4.7 to 6.8)
Incident HF diagnosed at beginning of the 5-y interval	4.9 (1.3 to 8.5)	5.3 (3.2 to 7.4)	7.1 (4.5 to 9.7)	10.3 (6.4 to 14.1)
Difference (incident HF minus no HF)¶	3.4 (–0.3 to 7.1)	2.4 (0.2 to 4.6)	2.8 (0.2 to 5.4)	4.6 (0.6 to 8.5)
DSST by age and HF; in the absence of AF§				
No HF diagnosed before or during the 5-y interval	1.0 (0.8 to 1.2)	2.8 (2.6 to 3.0)	4.7 (4.4 to 5.0)	6.6 (6.1 to 7.0)
Incident HF diagnosed at beginning of the 5-y interval	1.5 (–1.5 to 4.5)	3.4 (1.5 to 5.2)	5.4 (3.1 to 7.6)	7.5 (3.6 to 11.5)
Difference (incident HF minus no HF)¶	0.6 (–2.5 to 3.6)	0.5 (–1.3 to 2.4)	0.7 (–1.6 to 2.9)	1.0 (–3.0 to 4.9)

3MSE indicates Modified Mini-Mental State Examination; AF, atrial fibrillation; DSST, Digit Symbol Substitution Test; and HF, heart failure.

*Adjusted for birth year, sex, race, education, cigarette smoking, alcohol use, β -blocker use, angiotensin-converting enzyme inhibitor use, systolic blood pressure, body mass index, chronic kidney disease, chronic obstructive pulmonary disease, anemia, diabetes mellitus, hypertension, and coronary heart disease.

†F test $P=0.027$ for whether 3MSE trajectories differed overall by AF status.

‡F test $P=0.084$ for whether the difference in 3MSE trajectory by incident HF further differed by AF status.

§F test $P=0.339$ for whether DSST trajectories differed overall by AF status.

¶F test $P=0.505$ for whether the difference in DSST trajectory by incident HF further differed by AF status.

Based on our results, older adults who were diagnosed with HF were more likely than their peers with no history of HF to show global cognitive deficits or processing speed deficits, even when HF was first diagnosed. People with HF then experienced, on average, more rapid subsequent decline in global cognitive performance than people who had no history of HF. This association was not significantly different by AF status or by EF category. It remains to be seen whether early and consistent optimal HF management can counteract or prevent associated decline in cognitive function in people with HF.

Table 5. Model-Predicted 5-y Decline in Mean 3MSE Score and DSST Score After Incident HF Diagnosis, by Left Ventricular EF Category

EF Category	Predicted 5-y Decline (95% Confidence Interval)*	
	3MSE Analysis†	DSST Analysis‡
Reduced EF	5.8 (2.3–9.3)	4.6 (1.7–7.6)
Preserved EF	7.7 (4.6–10.8)	4.9 (2.1–7.6)
Unknown EF	6.8 (4.2–9.5)	7.3 (4.9–9.8)

3MSE indicates Modified Mini-Mental State Examination; DSST, Digit Symbol Substitution Test; EF, ejection fraction; and HF, heart failure.

*Adjusted for age at incident HF diagnosis, sex, race, and education.

†F test $P=0.734$ for the difference in 3MSE trajectories by EF category.

‡F test $P=0.280$ for the difference in DSST trajectories by EF category.

SOURCES OF FUNDING

This research was supported by contracts HHSN 268201200036C, HHSN268200800007C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086, N01HC85084, and N01HC35129 and grants U01HL080295 and U01HL130114 from the National Heart, Lung, and Blood Institute (NHLBI), with additional contribution from the National Institute of Neurological Disorders and Stroke. Additional support was provided by R01AG023629 from the National Institute on Aging. A full list of principal CHS (Cardiovascular Health Study) investigators and institutions can be found at <http://chs-nhlbi.org>. Dr Heckbert was supported by R01 HL127659 from NHLBI. Dr Thacker has received a Clinical Research Loan Repayment Program award from NHLBI.

DISCLOSURES

None.

AFFILIATIONS

From the Department of Statistics (C.A.H., N.J.B.) and Department of Public Health (E.L.T.), Brigham Young University, Provo, UT; Department of Internal Medicine, Yale School of Medicine, New Haven, CT (S.I.C.); Department of Medicine (J.A.D.) and Department of Population Health (J.A.D.), New York

University Langone Medical Center; Cardiovascular Health Research Unit (S.R.H., B.M.P., C.M.S.), Department of Neurology (W.T.L.), Department of Epidemiology (W.T.L., S.R.H., B.M.P., S.D.), Department of Medicine (B.M.P., C.M.S.), Department of Health Services (B.M.P.), Department of Biostatistics (A.M.A.), and Department of Psychiatry and Behavioral Sciences (S.M.T.), University of Washington, Seattle; Kaiser Permanente Washington Health Research Institute, Seattle (S.R.H., B.M.P., S.D.); Department of Medicine, Rutgers New Jersey Medical School, Newark (J.M.G.); Geriatric Research, Education, and Clinical Center, Seattle VA Medical Center, WA (S.M.T.); Department of Medicine, Duke University School of Medicine, Durham, NC (M.G.N.); Department of Neurology, Johns Hopkins University, Baltimore, MD (R.F.G.); and Department of Epidemiology (A.B.N.), Department of Medicine (A.B.N.), and Clinical and Translational Science Institute (A.B.N.), University of Pittsburgh, PA.

FOOTNOTES

Received August 7, 2017; accepted January 23, 2018.

The content in this article is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

An early version of this work was presented at the American Heart Association Epidemiology and Prevention Conference, Baltimore, MD, March 2015.

The Data Supplement is available at <http://circheartfailure.ahajournals.org/lookup/suppl/doi:10.1161/CIRCHEARTFAILURE.117.004476/-/DC1>.

Circ Heart Fail is available at <http://circheartfailure.ahajournals.org>.

REFERENCES

- Qiu C, Winblad B, Marengoni A, Klarin I, Fastbom J, Fratiglioni L. Heart failure and risk of dementia and Alzheimer disease: a population-based cohort study. *Arch Intern Med*. 2006;166:1003–1008. doi: 10.1001/archinte.166.9.1003.
- Tilvis RS, Kähönen-Väre MH, Jolkkonen J, Valvanne J, Pitkala KH, Strandberg TE. Predictors of cognitive decline and mortality of aged people over a 10-year period. *J Gerontol A Biol Sci Med Sci*. 2004;59:268–274. doi: 10.1093/gerona/59.3.M268.
- Vogels RLC, Scheltens P, Schroeder-Tanka JM, Weinstein HC. Cognitive impairment in heart failure: a systematic review of the literature. *Eur J Heart Fail*. 2007;9:440–449. doi: 10.1016/j.ejheart.2006.11.001.
- Dodson JA, Chaudhry SI. Geriatric conditions in heart failure. *Curr Cardiovasc Risk Rep*. 2012;6:404–410. doi: 10.1007/s12170-012-0259-8.
- Ampadu J, Morley JE. Heart failure and cognitive dysfunction. *Int J Cardiol*. 2015;178:12–23. doi: 10.1016/j.ijcard.2014.10.087.
- Dodson JA, Truong T-TN, Towle VR, Kerins G, Chaudhry SI. Cognitive impairment in older adults with heart failure: prevalence, documentation, and impact on outcomes. *Am J Med*. 2013;126:120–126. doi: 10.1016/j.amjmed.2012.05.029.
- Murad K, Goff DC Jr, Morgan TM, Burke GL, Bartz TM, Kizer JR, Chaudhry SI, Gottdiener JS, Kitzman DW. Burden of comorbidities and functional and cognitive impairments in elderly patients at the initial diagnosis of heart failure and their impact on total mortality: the Cardiovascular Health Study. *JACC Heart Fail*. 2015;3:542–550. doi: 10.1016/j.jchf.2015.03.004.
- Hajduk AM, Kiefe CI, Person SD, Gore JG, Saczynski JS. Cognitive change in heart failure: a systematic review. *Circ Cardiovasc Qual Outcomes*. 2013;6:451–460. doi: 10.1161/CIRCOUTCOMES.113.000121.
- Alosco ML, García S, Spitznagel MB, van Dulmen M, Cohen R, Sweet LH, Josephson R, Hughes J, Rosneck J, Gunstad J. Cognitive performance in older adults with stable heart failure: longitudinal evidence for stability and improvement. *Neuropsychol Dev Cogn B Aging Neuropsychol Cogn*. 2014;21:239–256. doi: 10.1080/13825585.2013.818616.
- Hjelm C, Dahl A, Broström A, Mårtensson J, Johansson B, Strömberg A. The influence of heart failure on longitudinal changes in cognition among individuals 80 years of age and older. *J Clin Nurs*. 2012;21:994–1003. doi: 10.1111/j.1365-2702.2011.03817.x.
- Alwerdt J, Edwards JD, Athilingam P, O'Connor ML, Valdés EG. Longitudinal differences in cognitive functioning among older adults with and without heart failure. *J Aging Health*. 2013;25:1358–1377. doi: 10.1177/0898264313505111.
- Almeida OP, Beer C, Lautenschlager NT, Arnolda L, Alfonso H, Flicker L. Two-year course of cognitive function and mood in adults with congestive heart failure and coronary artery disease: the Heart-Mind Study. *Int Psychogeriatr*. 2012;24:38–47. doi: 10.1017/S1041610211001657.
- Verhaegen P, Borchelt M, Smith J. Relation between cardiovascular and metabolic disease and cognition in very old age: cross-sectional and longitudinal findings from the Berlin Aging Study. *Health Psychol*. 2003;22:559–569. doi: 10.1037/0278-6133.22.6.559.
- Thacker EL, McKnight B, Psaty BM, Longstreth WT Jr, Sitlani CM, Dublin S, Arnold AM, Fitzpatrick AL, Gottesman RF, Heckbert SR. Atrial fibrillation and cognitive decline: a longitudinal cohort study. *Neurology*. 2013;81:119–125. doi: 10.1212/WNL.0b013e31829a33d1.
- Myserlis PG, Malli A, Kalaitzoglou DK, Kalaitzidis G, Miliogkos M, Kokkinidis DG, Kalogeropoulos AP. Atrial fibrillation and cognitive function in patients with heart failure: a systematic review and meta-analysis. *Heart Fail Rev*. 2017;22:1–11. doi: 10.1007/s10741-016-9587-y.
- Bratzke-Bauer LC, Pozehl BJ, Paul SM, Johnson JK. Neuropsychological patterns differ by type of left ventricle dysfunction in heart failure. *Arch Clin Neuropsychol*. 2013;28:114–124. doi: 10.1093/arclin/acs101.
- Athilingam P, D'Aouost RF, Miller L, Chen L. Cognitive profile in persons with systolic and diastolic heart failure. *Congest Heart Fail*. 2013;19:44–50. doi: 10.1111/chf.12001.
- Fried LP, Borhani NO, Enright P, Furberg CD, Gardin JM, Kronmal RA, Kuller LH, Manolio TA, Mittelmark MB, Newman A. The Cardiovascular Health Study: design and rationale. *Ann Epidemiol*. 1991;1:263–276. doi: 10.1016/1047-2797(91)90005-W.
- Psaty BM, Kuller LH, Bild D, Burke GL, Kittner SJ, Mittelmark M, Price TR, Rautaharju PM, Robbins J. Methods of assessing prevalent cardiovascular disease in the Cardiovascular Health Study. *Ann Epidemiol*. 1995;5:270–277. doi: 10.1016/1047-2797(94)00092-8.
- Psaty BM, Delaney JA, Arnold AM, Curtis LH, Fitzpatrick AL, Heckbert SR, McKnight B, Ives D, Gottdiener JS, Kuller LH, Longstreth WT Jr. Study of cardiovascular health outcomes in the era of claims data: the Cardiovascular Health Study. *Circulation*. 2016;133:156–164. doi: 10.1161/CIRCULATIONAHA.115.018610.
- Ives DG, Fitzpatrick AL, Bild DE, Psaty BM, Kuller LH, Crowley PM, Cruise RG, Theroux S. Surveillance and ascertainment of cardiovascular events. The Cardiovascular Health Study. *Ann Epidemiol*. 1995;5:278–285. doi: 10.1016/1047-2797(94)00093-9.
- Gottdiener JS, Arnold AM, Aurigemma GP, Polak JF, Tracy RP, Kitzman DW, Gardin JM, Rutledge JE, Boineau RC. Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. *J Am Coll Cardiol*. 2000;35:1628–1637. doi: 10.1016/S0735-1097(00)00582-9.
- Schellenbaum GD, Heckbert SR, Smith NL, Rea TD, Lumley T, Kitzman DW, Roger VL, Taylor HA, Psaty BM. Congestive heart failure incidence and prognosis: case identification using central adjudication versus hospital discharge diagnoses. *Ann Epidemiol*. 2006;16:115–122. doi: 10.1016/j.annepidem.2005.02.012.
- Psaty BM, Manolio TA, Kuller LH, Kronmal RA, Cushman M, Fried LP, White R, Furberg CD, Rautaharju PM. Incidence of and risk factors for atrial fibrillation in older adults. *Circulation*. 1997;96:2455–2461. doi: 10.1161/01.CIR.96.7.2455.
- Patton KK, Ellinor PT, Heckbert SR, Christenson RH, DeFilippi C, Gottdiener JS, Kronmal RA. N-terminal pro-B-type natriuretic peptide is a major predictor of the development of atrial fibrillation: the Cardiovascular Health Study. *Circulation*. 2009;120:1768–1774. doi: 10.1161/CIRCULATIONAHA.109.873265.
- Teng EL, Chui HC. The Modified Mini-Mental State (3MS) examination. *J Clin Psychiatry*. 1987;48:314–318.
- Brandt J, Spencer M, Folstein M. The telephone interview for cognitive status. *Neuropsychiatry Neuropsychol Behav Neurol*. 1988;1:111–117.
- Jorm AF, Scott R, Cullen JS, MacKinnon AJ. Performance of the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) as a screening test for dementia. *Psychol Med*. 1991;21:785–790.

29. Arnold AM, Newman AB, Dermond N, Haan M, Fitzpatrick A. Using telephone and informant assessments to estimate missing Modified Mini-Mental State Exam scores and rates of cognitive decline. The Cardiovascular Health Study. *Neuroepidemiology*. 2009;33:55–65. doi: 10.1159/000215830.
30. Wechsler D. *Wechsler Adult Intelligence Scale-Revised Manual*. New York, NY: Psychological Corporation; 1981.
31. Psaty BM, Lee M, Savage PJ, Rutan GH, German PS, Lyles M. Assessing the use of medications in the elderly: methods and initial experience in the Cardiovascular Health Study. The Cardiovascular Health Study Collaborative Research Group. *J Clin Epidemiol*. 1992;45:683–692. doi: 10.1016/0895-4356(92)90143-B.
32. Cushman M, Cornell ES, Howard PR, Bovill EG, Tracy RP. Laboratory methods and quality assurance in the Cardiovascular Health Study. *Clin Chem*. 1995;41:264–270.
33. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF III, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. *Ann Intern Med*. 2009;150:604–612. doi: 10.7326/0003-4819-150-9-200905050-00006.
34. Inzitari M, Studenski S, Rosano C, Zakai NA, Longstreth WT Jr, Cushman M, Newman AB. Anemia is associated with the progression of white matter disease in older adults with high blood pressure: the Cardiovascular Health Study. *J Am Geriatr Soc*. 2008;56:1867–1872. doi: 10.1111/j.1532-5415.2008.01950.x.
35. Longstreth WT Jr, Bernick C, Fitzpatrick A, Cushman M, Knepper L, Lima J, Furberg CD. Frequency and predictors of stroke death in 5,888 participants in the Cardiovascular Health Study. *Neurology*. 2001;56:368–375. doi: 10.1212/WNL.56.3.368: 1526-632X.
36. Fitzmaurice GM, Laird NM, Ware JH. *Applied Longitudinal Analysis*. Hoboken, NJ: John Wiley & Sons; 2004.
37. Euser SM, Schram MT, Hofman A, Westendorp RG, Breteler MM. Measuring cognitive function with age: the influence of selection by health and survival. *Epidemiology*. 2008;19:440–447. doi: 10.1097/EDE.0b013e31816a1d31.
38. Cermakova P, Eriksdotter M, Lund LH, Winblad B, Religa P, Religa D. Heart failure and Alzheimer's disease. *J Intern Med*. 2015;277:406–425. doi: 10.1111/ijim.12287.
39. Cannon JA, McMurray JJ, Quinn TJ. 'Hearts and minds': association, causation and implication of cognitive impairment in heart failure. *Alzheimers Res Ther*. 2015;7:22. doi: 10.1186/s13195-015-0106-5.
40. Jefferson AL, Himali JJ, Beiser AS, Au R, Massaro JM, Seshadri S, Gona P, Salton CJ, DeCarli C, O'Donnell CJ, Benjamin EJ, Wolf PA, Manning WJ. Cardiac index is associated with brain aging: the Framingham Heart Study. *Circulation*. 2010;122:690–697. doi: 10.1161/CIRCULATIONAHA.109.905091.
41. Russo C, Jin Z, Homma S, Elkind MS, Rundek T, Yoshita M, DeCarli C, Wright CB, Sacco RL, Di Tullio MR. Subclinical left ventricular dysfunction and silent cerebrovascular disease: the Cardiovascular Abnormalities and Brain Lesions (CABL) study. *Circulation*. 2013;128:1105–1111. doi: 10.1161/CIRCULATIONAHA.113.001984.
42. Kizer JR. Enhancing detection of subclinical end-organ damage: echocardiographic left ventricular strain holds up a mirror to the brain. *Circulation*. 2013;128:1045–1047. doi: 10.1161/CIRCULATIONAHA.113.004793.
43. Ogren JA, Fonarow GC, Woo MA. Cerebral impairment in heart failure. *Curr Heart Fail Rep*. 2014;11:321–329. doi: 10.1007/s11897-014-0211-y.
44. Alagiakrishnan K, Mah D, Ahmed A, Ezekowitz J. Cognitive decline in heart failure. *Heart Fail Rev*. 2016;21:661–673. doi: 10.1007/s10741-016-9568-1.
45. Kure CE, Rosenfeldt FL, Scholey AB, Pipingas A, Kaye DM, Bergin PJ, Croft KD, Wesnes KA, Myers SP, Stough C. Relationships among cognitive function and cerebral blood flow, oxidative stress, and inflammation in older heart failure patients. *J Card Fail*. 2016;22:548–559. doi: 10.1016/j.cardfail.2016.03.006.
46. Newman AB, Sanders JL, Kizer JR, Boudreau RM, Odden MC, Zeki AI, Hazzouri A, Arnold AM. Trajectories of function and biomarkers with age: the CHS All Stars Study. *Int J Epidemiol*. 2016;45:1135–1145. doi: 10.1093/ije/dyw092.

Long-Term Cognitive Decline After Newly Diagnosed Heart Failure: Longitudinal Analysis in the CHS (Cardiovascular Health Study)

Christa A. Hammond, Natalie J. Blades, Sarwat I. Chaudhry, John A. Dodson, W.T. Longstreth, Jr, Susan R. Heckbert, Bruce M. Psaty, Alice M. Arnold, Sascha Dublin, Colleen M. Sitlani, Julius M. Gardin, Stephen M. Thielke, Michael G. Nanna, Rebecca F. Gottesman, Anne B. Newman and Evan L. Thacker

Circ Heart Fail. 2018;11:

doi: 10.1161/CIRCHEARTFAILURE.117.004476

Circulation: Heart Failure is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231

Copyright © 2018 American Heart Association, Inc. All rights reserved.

Print ISSN: 1941-3289. Online ISSN: 1941-3297

The online version of this article, along with updated information and services, is located on the World Wide Web at:

<http://circheartfailure.ahajournals.org/content/11/3/e004476>

Data Supplement (unedited) at:

<http://circheartfailure.ahajournals.org/content/suppl/2018/03/08/CIRCHEARTFAILURE.117.004476.DC1>


Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Circulation: Heart Failure* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the [Permissions and Rights Question and Answer](#) document.

Reprints: Information about reprints can be found online at:
<http://www.lww.com/reprints>

Subscriptions: Information about subscribing to *Circulation: Heart Failure* is online at:
<http://circheartfailure.ahajournals.org/subscriptions/>

SUPPLEMENTAL MATERIAL

Supplemental Figure 1. Flowchart of participants and cognitive test scores for analysis



Summary of cognitive test scores not obtained or not analyzed due to censoring or missed exams during follow-up:

	3MSE analysis (n = 4,864 participants included)			DSST analysis (n = 4,969 participants included)		
	Overall	No prior history of HF	After incident HF	Overall	No prior history of HF	After incident HF
Number of potential scores if there were no censoring	36,759 (100%)	34,854 (100%)	1,905 (100%)	41,348 (100%)	39,400 (100%)	1,948 (100%)
Scores obtained and analyzed	34,854 (90.4%)	31,740 (91.1%)	1,495 (78.5%)	34,769 (84.1%)	33,599 (85.3%)	1,170 (60.1%)
Scores not obtained						
Censoring: death	4 (0.0%)	4 (0.0%)	0 (0.0%)	4 (0.0%)	4 (0.0%)	0 (0.0%)
Censoring: dropout	965 (2.6%)	825 (2.4%)	140 (7.3%)	4,389 (10.6%)	3,823 (9.7%)	566 (29.1%)
Intermittently missed exam	1,682 (4.6%)	1,555 (4.5%)	127 (6.7%)	1,403 (3.4%)	1,306 (3.3%)	97 (5.0%)
Scores obtained; not analyzed						
Censoring: incident stroke	873 (2.4%)	730 (2.1%)	143 (7.5%)	783 (1.9%)	668 (1.7%)	115 (5.9%)

Abbreviations: 3MSE = Modified Mini-Mental State Examination; CHS = Cardiovascular Health Study; DSST = Digit Symbol Substitution Test; EF = ejection fraction; HF = heart failure.

Participants with only one cognitive assessment: Of 4,864 participants included in the 3MSE analysis, 215 (4%) contributed only one 3MSE score to the analysis. Of 4,969 participants included in the DSST analysis, 293 (6%) contributed only one DSST score to the analysis.

Missing covariate values: In the 3MSE analysis, of 347 participants excluded due to missing covariate values, 183 (53%) were missing chronic obstructive pulmonary disease, another 74 (21%) were missing diabetes, and the remaining 90 (26%) were missing other covariates. In the DSST analysis, of 350 participants excluded due to missing covariate values, 188 (54%) were missing chronic obstructive pulmonary disease, another 77 (22%) were missing diabetes, and the remaining 85 (24%) were missing other covariates.

3MSE scores estimated from telephone-based cognitive assessments: In the 3MSE analysis, 1,163 3MSE scores with no prior history of HF and 163 3MSE scores after incident HF were estimated from telephone-based measures of global cognitive performance.¹

Supplemental Table 1. Characteristics at study enrollment and incident conditions by incident heart failure (HF) status for participants included in analysis of Digit Symbol Substitution Test (DSST)*

Characteristic†	Participants diagnosed with incident HF during follow-up (N = 389)	Participants not diagnosed with incident HF during follow-up (N = 4,580)
Age, y, mean (SD)	74.6 (5.8)	72.9 (5.3)
Birth year, mean (SD)	1915 (5.9)	1917 (5.4)
Male, %	52.7	40.8
Black race, %	9.5	14.0
Years of education through 12 th grade, mean (SD)	10.9 (2.0)	11.0 (1.9)
Any education beyond 12 th grade, %	43.2	43.9
Former smoking, %	44.7	41.6
Current smoking, %	11.6	11.9
Any current alcohol use, %	44.5	52.2
Drinks/week, mean (SD)	4.6 (7.2)	5.1 (8.6)
Beta-blocker use, %	18.0	12.2
Angiotensin converting enzyme inhibitor use, %	6.4	6.1
Systolic blood pressure, mm Hg, mean (SD)	140.3 (22.1)	135.6 (21.4)
Body mass index, kg/m ² , mean (SD)	27.5 (4.8)	26.5 (4.6)
Chronic kidney disease, %	44.0	37.1
Chronic obstructive pulmonary disease, %	16.5	12.2
Anemia, %	7.5	7.4
Diabetes		
At enrollment, %	22.9	13.8
Incident, %	8.0	4.1
Hypertension		
At enrollment, %	64.3	56.4
Incident, %	22.6	20.8
Coronary heart disease		
At enrollment, %	32.4	15.5
Incident, %	31.9	6.7
Atrial fibrillation		
At enrollment, %	5.1	1.7
Incident, %	37.5	6.3

* The 4,969 participants included in this table (389 + 4,580) had at least one Digit Symbol Substitution Test (DSST) score and were included in regression models for DSST.

† All percentages in the table are column percentages. Mean drinks per week was calculated among participants who reported any current alcohol use. For diabetes, hypertension, coronary heart disease, and atrial fibrillation, percentages of participants with the condition present at enrollment and of those with the incident condition occurring during follow-up were mutually exclusive and therefore sum to the total percentage of participants with the condition either present at enrollment or occurring during follow-up (mean of 6.5 years). Incident diabetes, hypertension, coronary heart disease, or atrial fibrillation may have occurred before or after incident HF diagnosis.

Supplemental Table 2. Coefficients and standard errors from regression models

	3MSE analysis		DSST analysis	
	Estimate	Standard error	Estimate	Standard error
Intercept	74.712	0.660	14.964	0.959
Age, per year*	-0.550	0.026	-0.529	0.019
Age-squared	-0.055	0.003	-0.037	0.002
Incident HF, yes vs no	-0.861	0.366	-1.227	0.422
Time since incident HF diagnosis, per year	-0.500	0.157	-0.293	0.167
Age × incident HF	-0.034	0.065	0.004	0.075
Age-squared × incident HF	-0.002	0.006	0.009	0.007
Age × time since incident HF diagnosis	-0.012	0.036	0.018	0.039
Age-squared × time since incident HF diagnosis	-0.004	0.003	-0.004	0.003
Birth year, per year*	0.065	0.032	0.431	0.035
Male vs female	-1.010	0.197	-3.423	0.301
Black race vs white race	-4.812	0.273	-8.856	0.432
Years of education through 12 th grade, per year	1.433	0.058	2.164	0.086
Any education beyond 12 th grade, yes vs no	1.960	0.205	3.907	0.318
Former smoking, yes vs never smoking	-0.053	0.204	-0.166	0.314
Current smoking, yes vs never smoking	-1.268	0.286	-3.838	0.458
Any current alcohol use, yes vs no	0.717	0.205	2.206	0.316
Drinks/d, per drink*	0.135	0.099	0.015	0.159
Beta-blocker use, yes vs no	0.640	0.274	0.082	0.423
Angiotensin converting enzyme inhibitor use, yes vs no	0.102	0.387	-1.127	0.592
Systolic blood pressure, per mm Hg*	-0.016	0.005	-0.030	0.007
Body mass index, per kg/m ² *	-0.003	0.020	-0.063	0.032
Chronic kidney disease, yes vs no	0.066	0.203	0.115	0.305
Chronic obstructive pulmonary disease, yes vs no	-0.300	0.275	-1.230	0.422
Anemia, yes vs no	-0.674	0.383	-2.542	0.558
Diabetes, yes vs no [†]	-0.305	0.215	-1.348	0.267
Hypertension, yes vs no [†]	0.233	0.156	0.186	0.164
Coronary heart disease, yes vs no [†]	-0.359	0.188	-0.522	0.223
Atrial fibrillation, yes vs no [†]	-0.200	0.249	-0.829	0.260

Abbreviations: 3MSE = Modified Mini-Mental State Examination; DSST = Digit Symbol Substitution Test; HF = heart failure.

* Age was centered at 77 years. Birth year was centered at 1917. Systolic blood pressure was centered at 135 mm Hg. Body mass index was centered at 26.68 kg/m². Drinks per day was drinks per week divided by 7.

[†] Diabetes, hypertension, coronary heart disease, and atrial fibrillation were time-varying variables, updated at the occurrence of incident diagnosis. All other variables were measured at enrollment.

Supplemental Table 3. Characteristics of four previously published studies with follow-up longer than one year, comparing longitudinal cognitive changes in adults with heart failure versus without heart failure

Study	Participants	Timing of cognitive assessments	Heart failure identification	Handling of prevalent and incident heart failure	Exclusion of participants based on attrition during follow-up	Results: HF significantly associated with faster cognitive decline	Results: HF not significantly associated with rate of cognitive decline
Hjelm, et al: Octogenarian Twin Study (OCTO-twin) within Swedish Twin Registry²	Ages \geq 80 N = 702 95 prevalent HF 96 incident HF 511 no HF	5 assessments spanning 8 years	Medical record review	Prevalent and incident HF grouped together; all cognitive test scores from incident HF cases, including those obtained before HF diagnosis, used to model cognitive trajectories in HF group	No participants excluded based on attrition; all available cognitive test scores used from participants who died or had missing cognitive assessments	Short-term memory: • Digit span Episodic memory: • Prose recall	Processing speed: • Digit symbol substitution • Picture matching Visuospatial ability: • Block design Semantic memory: • Information task • Verbal meaning Episodic memory: • Picture memory • Memory-in-reality
Alwerdt, et al: Advanced Cognitive Training for Independent and Vital Elderly Study (ACTIVE)³	Ages \geq 65 N = 692 35 prevalent HF 37 incident HF 620 no HF	6 assessments spanning 5 years	Participant self-report of being diagnosed with HF by doctor or nurse	Prevalent and incident HF cases analyzed as separate groups; all cognitive test scores from incident HF cases, including those obtained before HF diagnosis, used to model cognitive trajectories in incident HF group	No participants excluded based on attrition; all available cognitive test scores used from participants who died or had missing cognitive assessments	Reasoning: • Word series	Processing speed: • Complex reaction time • Useful field of view • Digit symbol substitution Memory: • Verbal learning • Behavioral memory stories • Auditory verbal learning Reasoning: • Letter sets • Letter series
Almeida, et al: Heart-Mind Study⁴	Ages \geq 45 N = 158 77 prevalent HF 81 no HF	3 assessments spanning 2 years	Standardized protocol; only participants with LVEF < 0.4 included in HF group	Prevalent HF cases analyzed; no ascertainment of incident HF	No participants excluded based on attrition; all available cognitive test scores used from participants who died or had missing cognitive assessments	Global cognitive ability: • CAMCOG	Processing speed: • Digit copying • Digit coding Memory: • Immediate recall • Short-delayed recall • Long-delayed recall
Verhaegen, et al: Berlin Aging Study (BASE)⁵	Ages \geq 70 N = 196 101 prevalent HF 49 incident HF 46 no HF	2 assessments spanning 4 years	Standardized protocol	Prevalent and incident HF cases analyzed as separate groups; baseline cognitive test scores obtained before HF diagnosis used to model cognitive change scores in incident HF group	Approximately 300 participants excluded who contributed baseline cognitive data but died or were lost to follow-up prior to second measurement occasion	None	Global cognitive ability: Composite of • Perceptual speed • Episodic memory • Fluency • Knowledge

Abbreviations: CAMCOG = Cambridge Cognitive Examination of the Elderly; HF = heart failure; LVEF = left ventricular ejection fraction.

SUPPLEMENTAL REFERENCES

1. Arnold AM, Newman AB, Dermond N, Haan M, Fitzpatrick A. Using telephone and informant assessments to estimate missing Modified Mini-Mental State Exam scores and rates of cognitive decline. The Cardiovascular Health Study. *Neuroepidemiology*. 2009;33:55-65. doi: 10.1159/000215830.
2. Hjelm C, Dahl A, Broström A, Mårtensson J, Johansson B, Strömberg A. The influence of heart failure on longitudinal changes in cognition among individuals 80 years of age and older. *J Clin Nurs*. 2012;21:994-1003. doi: 0.1111/j.1365-2702.2011.03817.x.
3. Alwerdt J, Edwards JD, Athilingam P, O'Connor ML, Valdés EG. Longitudinal differences in cognitive functioning among older adults with and without heart failure. *J Aging Health*. 2013;25:1358-1377. doi: 10.1177/0898264313505111.
4. Almeida OP, Beer C, Lautenschlager NT, Arnolda L, Alfonso H, Flicker L. Two-year course of cognitive function and mood in adults with congestive heart failure and coronary artery disease: the Heart-Mind Study. *Int Psychogeriatr*. 2012;24:38-47. doi: 10.1017/S1041610211001657.
5. Verhaegen P, Borchelt M, Smith J. Relation between cardiovascular and metabolic disease and cognition in very old age: cross-sectional and longitudinal findings from the berlin aging study. *Health Psychol*. 2003;22:559-569. doi: 10.1037/0278-6133.22.6.559.